Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis
Open Access
- 27 May 2020
- journal article
- letter
- Published by Wiley in HemaSphere
- Vol. 4 (3), e356
- https://doi.org/10.1097/hs9.0000000000000356
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great optionsCancer, 2019
- New Concepts of Treatment for Patients with MyelofibrosisCurrent Treatment Options in Oncology, 2019
- Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapyBlood, 2018
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre studyThe Lancet Haematology, 2017
- Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristicsLeukemia & Lymphoma, 2015
- Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistanceScientific Reports, 2015
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary MyelofibrosisJAMA Oncology, 2015
- Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcomeLeukemia Research, 2015
- Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patientsHaematologica, 2010
- Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatmentLeukemia, 2007